Scroll

idelalisib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
phosphatidylinositol 3-kinase inhibitors, antineoplastics	4878	870281-82-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: CAL 101 idelalisib zydelig CAL-101 GS-1101	Idelalisib is an inhibitor of PI3K-delta kinase, which is expressed in normal and malignant B-cells. Idelalisib induced apoptosis and inhibited proliferation in cell lines derived from malignant B-cells and in primary tumor cells. Idelalisib inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and the CXCR4 and CXCR5 signaling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Molecular weight: 415.43 Formula: C22H18FN7O CLOGP: 3.32 LIPINSKI: 0 HAC: 8 HDO: 2 TPSA: 99.16 ALOGS: -4.22 ROTB: 5 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

CAL 101
idelalisib
zydelig
CAL-101
GS-1101

Idelalisib is an inhibitor of PI3K-delta kinase, which is expressed in normal and malignant B-cells. Idelalisib induced apoptosis and inhibited proliferation in cell lines derived from malignant B-cells and in primary tumor cells. Idelalisib inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and the CXCR4 and CXCR5 signaling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow.

Molecular weight: 415.43
Formula: C22H18FN7O
CLOGP: 3.32
LIPINSKI: 0
HAC: 8
HDO: 2
TPSA: 99.16
ALOGS: -4.22
ROTB: 5

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.30	g	O

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
July 23, 2014	FDA	GILEAD SCIENCES INC
July 25, 2014	EMA

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Disease progression	1165.24	31.11	380	3236	122378	63363028
Death	108.26	31.11	119	3497	374262	63111144
Pneumonitis	106.70	31.11	48	3568	35174	63450232
Off label use	97.31	31.11	152	3464	674310	62811096
Diarrhoea	94.69	31.11	155	3461	715211	62770195
Colitis	83.56	31.11	45	3571	48483	63436923
Neutropenia	74.95	31.11	69	3547	174936	63310470
Cytomegalovirus infection	74.57	31.11	32	3584	20920	63464486
Non-small cell lung cancer	67.33	31.11	19	3597	3576	63481830
Chronic lymphocytic leukaemia recurrent	49.29	31.11	9	3607	235	63485171

Showing 1 to 10 of 26 entries

Previous1 2 3Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Disease progression	1460.87	27.92	581	5471	107496	34843383
Diarrhoea	205.92	27.92	291	5761	389621	34561258
Pneumonitis	190.22	27.92	100	5952	33778	34917101
Colitis	174.59	27.92	98	5954	37652	34913227
Pneumonia	85.68	27.92	191	5861	362436	34588443
Death	84.54	27.92	201	5851	397848	34553031
Chronic lymphocytic leukaemia recurrent	76.23	27.92	17	6035	393	34950486
Off label use	62.62	27.92	186	5866	419338	34531541
Pyrexia	58.76	27.92	157	5895	332856	34618023
Lymphocytosis	52.75	27.92	19	6033	2558	34948321

Showing 1 to 10 of 21 entries

Previous1 2 3Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Disease progression	2192.04	25.88	796	7858	183566	79552168
Colitis	228.06	25.88	125	8529	73182	79662552
Pneumonitis	226.62	25.88	117	8537	60743	79674991
Diarrhoea	225.40	25.88	366	8288	880123	78855611
Death	178.71	25.88	260	8394	566254	79169480
Pneumonia	118.55	25.88	236	8418	660010	79075724
Off label use	104.64	25.88	272	8382	906943	78828791
Neutropenia	97.47	25.88	137	8517	287573	79448161
Dehydration	95.91	25.88	126	8528	248061	79487673
Pyrexia	91.23	25.88	216	8438	678493	79057241

Showing 1 to 10 of 42 entries

Previous1 2 3 4 5Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	L01EM01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Phosphatidylinositol-3-kinase (Pi3K) inhibitors
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:50914	PI(3)K inhibitor
CHEBI has role	CHEBI:68495	Type I cell-death inducers
FDA EPC	N0000175605	Kinase Inhibitor
FDA MoA	N0000175082	Kinase Inhibitors
FDA MoA	N0000190114	Cytochrome P450 3A Inhibitors
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D004791	Enzyme Inhibitors

Showing 1 to 9 of 9 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID
Chronic lymphoid leukemia, disease	indication	92814006
Malignant lymphoma - small lymphocytic	indication	302841002
Follicular non-Hodgkin's lymphoma	indication	308121000
Toxic epidermal necrolysis due to drug	contraindication	402744003

Showing 1 to 4 of 4 entries

Previous1Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.29	acidic
pKa2	4.22	Basic
pKa3	2.56	Basic

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
100MG	ZYDELIG	GILEAD SCIENCES INC	N205858	July 23, 2014	RX	TABLET	ORAL	8980901	May 12, 2025	FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL
100MG	ZYDELIG	GILEAD SCIENCES INC	N205858	July 23, 2014	RX	TABLET	ORAL	9149477	May 12, 2025	INHIBITION ON PI3K KINASE
100MG	ZYDELIG	GILEAD SCIENCES INC	N205858	July 23, 2014	RX	TABLET	ORAL	RE44599	July 21, 2025	FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL
100MG	ZYDELIG	GILEAD SCIENCES INC	N205858	July 23, 2014	RX	TABLET	ORAL	RE44599	July 21, 2025	FOR THE TREATMENT OF PATIENTS WITH RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA OR [RELAPSED] SMALL LYMPHOCYTIC LYMPHOMA
100MG	ZYDELIG	GILEAD SCIENCES INC	N205858	July 23, 2014	RX	TABLET	ORAL	9492449	March 11, 2030	IN COMBINATION WITH RITUXIMAB, FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
100MG	ZYDELIG	GILEAD SCIENCES INC	N205858	July 23, 2014	RX	TABLET	ORAL	8865730	March 5, 2033	FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL
150MG	ZYDELIG	GILEAD SCIENCES INC	N205858	July 23, 2014	RX	TABLET	ORAL	8980901	May 12, 2025	FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL
150MG	ZYDELIG	GILEAD SCIENCES INC	N205858	July 23, 2014	RX	TABLET	ORAL	9149477	May 12, 2025	INHIBITION ON PI3K KINASE
150MG	ZYDELIG	GILEAD SCIENCES INC	N205858	July 23, 2014	RX	TABLET	ORAL	RE44599	July 21, 2025	FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL
150MG	ZYDELIG	GILEAD SCIENCES INC	N205858	July 23, 2014	RX	TABLET	ORAL	RE44599	July 21, 2025	FOR THE TREATMENT OF PATIENTS WITH RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA OR [RELAPSED] SMALL LYMPHOCYTIC LYMPHOMA

Showing 1 to 10 of 12 entries

Previous1 2Next

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Kinase	O00329	PK3CD_HUMAN	INHIBITOR	IC50	8.60	SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
DNA-dependent protein kinase catalytic subunit	Kinase	P78527	PRKDC_HUMAN		IC50	5.17	CHEMBL
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Kinase	P42338	PK3CB_HUMAN		IC50	6.25	SCIENTIFIC LITERATURE
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Kinase	P42336	PK3CA_HUMAN		IC50	6.09	SCIENTIFIC LITERATURE
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Kinase	P48736	PK3CG_HUMAN		IC50	7.05	SCIENTIFIC LITERATURE
Phosphatidylinositol 3-kinase catalytic subunit type 3	Kinase	Q8NEB9	PK3C3_HUMAN		IC50	5.36	CHEMBL
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Kinase		PK3CG_MOUSE		IC50	5.88	CHEMBL

Showing 1 to 7 of 7 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
015626	NDDF
11625818	PUBCHEM_CID
1544460	RXNORM
226727	MMSL
30429	MMSL
4033559	VUID
4033559	VANDF
40L	PDB_CHEM_ID
6741	IUPHAR_LIGAND_ID
709283009	SNOMEDCT_US

Showing 1 to 10 of 21 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Zydelig	HUMAN PRESCRIPTION DRUG LABEL	1	61958-1701	TABLET, FILM COATED	100 mg	ORAL	NDA	33 sections
Zydelig	HUMAN PRESCRIPTION DRUG LABEL	1	61958-1701	TABLET, FILM COATED	100 mg	ORAL	NDA	33 sections
Zydelig	HUMAN PRESCRIPTION DRUG LABEL	1	61958-1702	TABLET, FILM COATED	150 mg	ORAL	NDA	33 sections
Zydelig	HUMAN PRESCRIPTION DRUG LABEL	1	61958-1702	TABLET, FILM COATED	150 mg	ORAL	NDA	33 sections

Showing 1 to 4 of 4 entries

Previous1Next